EMA Authorised: Lytenava (bevacizumab) — Outlook Therapeutics NL B. V.

View source ↗

Summary

EMA authorised Lytenava (bevacizumab) for wet age-related macular degeneration, marking an approved product from Outlook Therapeutics NL B. V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Macular Degeneration

Drugs mentioned

• Lytenava (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration. MAH: Outlook Therapeutics NL B. V.. Decision date: 30/07/2026